Zydus receives final approval from the USFDA for Clindamycin Phosphate Topical Solution USP

Zydus receives final approval from the USFDA for Clindamycin Phosphate Topical Solution USP Ahmedabad, 17 July, 2018 Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate Topical Solution USP ( Cleocin T), 1%. Clindamycin is an antibiotic which works by stopping the growth of bacteria. It is used to treat acne and helps to decrease the number of acne lesions. It will be manufactured at group’s Topical manufacturing facility at Ahmedabad. In line with this, the group now has 204 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 22,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗